Seattle Genetic Advances ADC Pipeline
In the wake of the first-ever marketed antibody-drug conjugate (ADC) compound, Seattle Genetics continues to mine its rich therapeutic platform. This week, the company announced the initiation of two Phase 1 clinical trials in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.